Women's sexual dysfunctions correlate most strongly with poor mental health and with negative feelings for the partner, rather than with any serum hormone (or hormone metabolite) levels.
Normal changes with age and relationship duration must not be mistaken for desire/interest disorder. Desire disorder is diagnosed when there is a lack of anticipatory sexual desire, and desire (along with pleasure, arousal, and excitement) cannot be triggered during sexual activity and results in distress.
The most common syndrome is lack of initial desire, little subjective arousal (mental sexual excitement) such that desire is not triggered during any portion of the sexual engagement, and infrequent or no orgasm.
Given the sensitive nature of the information collected and reluctance/embarrassment to disclose at initial appointments, the clinician should continue to assess relevant information and integrate into treatment throughout contact with the patient.
Treatment includes components of psycho-education, cognitive behavioural therapy (CBT), sex therapy, mindfulness and psychotherapy, and occasionally medicines.
Women's sexual dysfunctions include a spectrum of disorders that are typically multi-factorial in aetiology and include sexual interest/arousal disorder (SIAD), female orgasmic disorder (FOD), and genito-pelvic penetration pain disorder (GPPPD), which combines the frequently overlapping diagnoses of vaginismus and dyspareunia. 
There are three criteria for diagnosing a sexual disorder: symptoms need to have persisted for a minimum of 6 months, they need to have been experienced in all or almost all (75% to 100%) sexual encounters or were recurrent, and to have caused clinically significant distress.  Poor mental health, stress,  and low levels of emotional intimacy between the partners correlate closely with dysfunction,    whereas serum levels of sex hormones do not.      
Vaginismus and dyspareunia, now grouped as GPPPD, are specific conditions that will not be covered in this topic; however, further information is available in the dyspareunia topic.
There is only limited research on persistent genital arousal disorder (PGAD)  and its pathophysiology and treatment are not well understood.
University of British Columbia
Departments of Psychiatry and Obstetrics/Gynecology
RB is an author or co-author of several references cited in this monograph. RB's department has received research funding from the Canadian Institutes of Health Research (CIHR).
Dr Rosemary Basson would like to gratefully acknowledge Dr Lori Brotto, a previous contributor to this monograph. LB is an author or co-author of several references cited in this monograph.
Johns Hopkins University
Division of Obstetrics and Gynecology
MBB declares that she has no competing interests.
Archway Sexual Health Clinic
PK has undertaken research studies for Boehringer Ingelheim.
Use of this content is subject to our disclaimer